This phase Ib/II trial studies the side effects and best dose of venetoclax in combination with quizartinib and how well they work in treating patients with acute myeloid leukemia that has come back or does not respond to treatment, and who are FLT3-mutation positive. Venetoclax and quizartinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Est. Enrollment: 32 participants
Study Start Date: Jan 25, 2019
Study Completion Date: Dec 31, 2021
Age: 18+ years